Novartis pelacarsen trial fails endpoint
Analysis based on 12 articles · First reported Sep 04, 2026 · Last updated Sep 05, 2026
The failed trial removes a potential future revenue stream for Royalty Pharma and Ionis, but Royalty Pharma's protective structure limits downside. Novartis faces a setback in its cardiovascular pipeline, while Ionis loses expected milestone payments.
Royalty Pharma announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide for patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), did not meet its primary endpoint of reducing cardiovascular events compared to placebo. Novartis plans to present the data at an upcoming medical congress. Royalty Pharma's $500 million funding agreement with Ionis was structured protectively, with $150 million allocated to pelacarsen royalties and $350 million to Spinraza royalties. Royalty Pharma expects to recoup its investment and earn a modest positive return, reiterates its 2030 Portfolio Receipts target of $4.7 billion or more, and does not anticipate making milestone payments to Ionis. Its Spinraza royalty interest will revert to Ionis after royalty payments reach $550 million, representing a 1.1x return.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard